Cardiac stent leading listed companies are LP (Beijing) Medical Devices Co.
Leopold (Beijing) Medical Devices Co., Ltd. was founded in 1999, is China's earliest engaged in the development and manufacture of cardiac interventional medical equipment, one of the enterprises. 20 years, the company has always been focusing on a full range of services for cardiovascular patients, to innovation-driven high-quality development, has become the leading cardiovascular health industry platform, the main business covering the medical devices, pharmaceuticals, medical services and health management of three major sectors. Its main business covers medical devices, pharmaceuticals, medical services and health management in three major sectors, and has been awarded the "National Heart Disease Implantation Interventional Diagnostic Devices and Equipment Engineering Technology Research Center" by the Ministry of Science and Technology of the People's Republic of China.
The company's self-developed bio-absorbable stents, cutting balloons, drug balloons, biodegradable blockers, TAVR valves, and artificial intelligence ECG automatic analysis and diagnostic system have reached the international leading level.
Leep Medical's development history
May 25, 2022, Leep Medical announced that the company's controlling subsidiary, Beijing Leep Diagnostics Science and Technology Co., Ltd. independently developed and produced the Monkeypox Virus Nucleic Acid Detection Kit (PCR-Fluorescent Probe Method) obtained the CE registration certificate.
In May 2022, Lepu Diagnostics, a subsidiary of Lepu Healthcare, added new products to its IVDD Class b products, successfully completed the expansion of the certificate, and formally obtained the CE certification in the European Union. The new products include blood glucose, ketone body, uric acid analyzer and blood glucose test strips, ketone body test strips, uric acid test strips.
On July 25, 2022, LPMC announced that the issuance of GDRs and listing on the SIX Swiss Exchange was conditionally approved by the SIX Swiss Exchange Supervisory Authority.
On September 22, 2022, LPH announced that the issuance of GDRs was listed on the SIX Swiss Exchange on September 21, 2022 (Swiss time).
On November 30, 2022, LPMC announced that the Company's self-developed single-use pressure microcatheter was recently approved for registration by the State Drug Administration and obtained the registration certificate for Class III medical device.
Reference for the above: Baidu Encyclopedia - LP (Beijing) Medical Devices Co.